Source: http://www.google.com/patents/US20040133145?dq=5958006
Timestamp: 2016-08-26 17:44:16
Document Index: 473331789

Matched Legal Cases: ['application No. 02', 'Application No. 60', 'art 141', 'art 141', 'art 141', 'art 143', 'art 143', 'art 143']

Patent US20040133145 - Device and process for extracorporeal treatment by citrate anticoagulant - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsThe invention concerns a device for treating blood by extracorporeal circulation (101) comprising a filter (102) having a first chamber (103) and a second chamber (104) separated by a semi-permeable membrane (105), an arterial line (106) connected to the first chamber (103) of the filter (102), a venous...http://www.google.com/patents/US20040133145?utm_source=gb-gplus-sharePatent US20040133145 - Device and process for extracorporeal treatment by citrate anticoagulantAdvanced Patent SearchPublication numberUS20040133145 A1Publication typeApplicationApplication numberUS 10/739,273Publication dateJul 8, 2004Filing dateDec 19, 2003Priority dateDec 20, 2002Also published asUS7351218Publication number10739273, 739273, US 2004/0133145 A1, US 2004/133145 A1, US 20040133145 A1, US 20040133145A1, US 2004133145 A1, US 2004133145A1, US-A1-20040133145, US-A1-2004133145, US2004/0133145A1, US2004/133145A1, US20040133145 A1, US20040133145A1, US2004133145 A1, US2004133145A1InventorsBernard BeneOriginal AssigneeHospal International Marketing Management Snc, Gambro Lundia Ab.Export CitationBiBTeX, EndNote, RefManPatent Citations (25), Referenced by (30), Classifications (14), Legal Events (6) External Links: USPTO, USPTO Assignment, EspacenetDevice and process for extracorporeal treatment by citrate anticoagulant
US 20040133145 A1Abstract
The invention concerns a device for treating blood by extracorporeal circulation (101) comprising a filter (102) having a first chamber (103) and a second chamber (104) separated by a semi-permeable membrane (105), an arterial line (106) connected to the first chamber (103) of the filter (102), a venous line (108) issuing from the first chamber (103) of the filter (102), a channel (109) used for pre-infusion of a substance for regional anticoagulation and linked to the arterial line (106), a purge channel (110) issuing from the second chamber (104) of the filter (102), an air separator (112) on the venous line (108), a line (112) for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood downstream of the air separator (111), and an air detector (113) downstream of the post-infusion line (112). Finally, the invention concerns a method for treating blood by extracorporeal circulation. Images(4) Claims(31)
1. Device for treating blood by extracorporeal circulation comprising: a filter having a first chamber and a second chamber separated by a semi-permeable membrane, an arterial line connected to the first chamber of the filter, a venous line issuing from the first chamber of the filter, a channel used for pre-infusion of a substance for local anticoagulation and linked to the arterial line, a purge channel issuing from the second chamber of the filter, an air separator on the venous line, a line for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood downstream of the air separator, an air detector downstream of the post-infusion line. 2. Device for treating blood by extracorporeal circulation according to claim 1, wherein no other air separator is inserted downstream of the air detector. 3. Device for treating blood by extracorporeal circulation according to claim 1 or 2, wherein said air separator is the only air separator present in the venous line and does not contain an air detector. 4. Device for treating blood by extracorporeal circulation according to claim 1, wherein the venous line comprises a channel which can receive an occlusion means downstream of the air detector. 5. Device for treating blood by extracorporeal circulation according to claim 4, wherein the occlusion means is a clamp. 6. Device for treating blood by extracorporeal circulation according to claim 1, wherein the post-infusion line is mounted immediately upstream of the air detector. 7. Device for treating blood by extracorporeal circulation according to claim 1 wherein the tube portion extending between the air detector and the connector to the patient is adapted not to receive any further line or any further injection device. 8. Device for treating blood by extracorporeal circulation according to claim 1 wherein the venous line comprises a patient venous line connector and the air detector operates directly upstream said patient venous line connector. 9. Device for treating blood by extracorporeal circulation according to claim 1, wherein the air separator comprises a bubble trap. 10. Device for treating blood by extracorporeal circulation according to one claim 1, wherein the solution for regional anticoagulation contains citrate ions. 11. Device for treating blood by extracorporeal circulation according to claim 10, wherein the solution for regional anticoagulation contains a solution of trisodium citrate dihydrate. 12. Device for treating blood by extracorporeal circulation according to claim 10, wherein the solution for regional anticoagulation contains a solution of Anticoagulant Citrate Dextrose (ACD) comprising trisodium citrate dihydrate and citric acid monohydrate. 13. Device for treating blood by extracorporeal circulation according to claim 1, wherein the solution at least partially re-establishing the ionic equilibrium of the blood contains calcium ions. 14. Device for treating blood by extracorporeal circulation according to claim 13, wherein the solution at least partially re-establishing the ionic equilibrium of the blood contains an isotonic solution comprising calcium chloride, potassium chloride and magnesium chloride. 15. Device for treating blood by extracorporeal circulation according to claim 1 comprising means for regulating the blood flow rate, the pre-infusion line being connected to the arterial line upstream said regulating means. 16. Device for treating blood by extracorporeal circulation according to claim 1 wherein the pre-infusion line is connected immediately downstream of the patient arterial line connector. 17. Device for treating blood by extracorporeal circulation according claim 15, wherein said regulating means comprises first means for regulating the flowrate of blood associated with the arterial line. 18. Device for treating blood by extracorporeal circulation according to claim 17, wherein said regulating means comprises second means for regulating the flow rate of liquid operationnaly associated with the pre-infusion line. 19. Device for treating blood by extracorporeal circulation according to claim 18, wherein said regulating means comprises third means for regulating the flow rate of liquid operationally associated with the post-infusion line. 20. Device for treating blood by extracorporeal circulation according to claim 19, wherein said regulating means comprises fourth means for regulating the flow rate of liquid operationaly associated with the purge line issuing from the second chamber of the filter. 21. Device for treating blood by extracorporeal circulation according to claim 15 comprising first means for measuring the flow rate of liquid operating on the purge channel and comprising a calculation and control unit for receiving the signals emitted by said measuring means and for controlling one or more means for regulating the flow rate. 22. Device for treating blood by extracorporeal circulation according to claim 15, comprising an intake line to the second chamber of the filter connecting up with a source of dialysis liquid. 23. Device for treating blood by extracorporeal circulation according to claim 22, wherein the dialysis liquid does not comprise calcium ions. 24. Device for treating blood by extracorporeal circulation according to claims 20, 21 and 22, comprising a second means for measuring the flowrate of liquid operating on the intake line and fifth means for regulating the flowrate of liquid operating on the intake line. 25. Device for treating blood by extracorporeal circulation according to claim 24, wherein the calculation and -control unit receive the signals emitted by one or more means for measuring the flowrate of liquid and controls one or more means for regulating the flowrate of liquid in order to initiate a haemofiltration or haemodiafiltration operating mode. 26. Device for treating blood by extracorporeal circulation according to claim 15, wherein each means of regulating the flowrate of liquid comprises a pump or a valve. 27. Device for treating blood by extracorporeal circulation according to claim 21 or 24 wherein the means of measuring the flowrate of liquid comprises a flow meter. 28. Device for treating blood by extracorporeal circulation according to claim 1, comprising a first balance for weighing a first reservoir connected to the pre-infusion line and containing the pre-infusion liquid. 29. Device for treating blood by extracorporeal circulation according to claim 28, comprising a second balance for weighing a second reservoir connected to the post-infusion line and containing the post-infusion liquid. 30. Device for treating blood by extracorporeal circulation according to claim 15 in combination with claim 28 or 29, comprising a calculation and control unit for receiving the signals emitted by at least one of the two balances and for controlling one or more means of regulating the flowrate of liquid. 31. Method of treating blood, comprising the following steps: infusing a substance for regional anti-coagulation into an arterial line carrying blood extracted from a patient, passing the extracted blood through a filter and to a venous line, after passage of the blood through the filter, eliminating the presence of air in the blood circulating in the venous line, after elimination of air, infusing a solution at least partially re-establishing the ionic equilibrium of the blood, after infusion of said re-establishing solution detecting the presence of air, in the event of air being detected, clamping the venous line downstream of the post-infusion, without passing through a second air separator placed downstream of the first air separator. Description
CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims the priority of French patent application No. 02 16228, filed on Dec. 20, 2002, and the benefit of U.S. Provisional Application No. 60/453 967, filed on Mar. 13, 2003, the contents of which are incorporated herein by reference. [0002] The present invention relates to a device for treating blood by extracorporeal circulation, a disposable line for use in a circuit for extracorporeal circulation of blood having undergone pre-infusion of anticoagulant, and a method for anticoagulation of the blood treated by extracorporeal circulation. [0003] A haemodialysis session requires anticoagulation of the blood circulating in the extracorporeal circulation line in order to avoid coagulation of the blood in contact with the synthetic materials (circulation lines, dialyser fibres) . This anticoagulation is most often performed using heparin, which is known for its anticoagulant properties. Heparin is injected as pre-infusion into the arterial line of the device, and it is then present in the entire extracorporeal circuit of the blood, from pre-infusion until re-injection of the blood into the patient. Consequently, upon return of the blood, the patient is administered doses of heparin. Although it is necessary to prevent coagulation in the extracorporeal circulation line, in some cases the risk of the patient bleeding may pose a danger. This is particularly true of patients at high risk of haemorrhaging (for example in the days following major surgery) or in those patients with hypersensitivity to heparin. Consequently, anti-coagulation with heparin may prove dangerous to the patient on account of heparin being injected via the return of blood to the patient. [0004] [0004]FIG. 1 shows a device for treating blood by extracorporeal circulation 1 according to the prior art, comprising a filter 2 having a first chamber 3 and a second chamber 4 separated by a semi-permeable membrane 5. The device comprises an arterial line 6 connected to the first chamber 3 of the filter for the circulation of blood taken from a patient 7, and a venous line 8 issuing from the first chamber of the filter. A pre-infusion channel 9 is connected to a container 10 comprising a solution of heparin and is linked to the arterial line 6, the function of the solution being to prevent coagulation of the blood outside the patient's body, and a purge channel 11 issuing from the second chamber 4 of the filter. An air separator 12 is linked to the venous line 8. The air separator 12 also comprises an air detector 13, and a clamp 14 is placed on the venous line 8 downstream of the air separator 12, that is to say downstream in the direction of circulation of the blood in the venous line 8. The clamp allows the flow of blood to be arrested in the event of air bubbles being detected by the detector 13 before the blood returns to the patient 7. [0005] Thus, as was mentioned above, the solution of heparin acts against coagulation of the blood throughout the device 1 and also in the patient's body. Consequently, the return and injection of heparin into the body of the patient 7 can prove dangerous. [0006] Patent application PCT/EP00/03583 concerns an infusion fluid of substitution, in particular for use in haemofiltration of blood, and an anticoagulant solution with citrate for regional anticoagulation. In order to avoid coagulation of blood during a haemodialysis session, it is known that citrate ions can be used as anticoagulant. The citrate ions, added to the blood in the extracorporeal circuit before they enter the artificial kidney, are active as anticoagulants. Thus, the risk of complications with bleeding due to systematic anticoagulation is avoided. During the haemofiltration, some of the citrate ions pass through the artificial kidney. The citrate ions are active as anticoagulants only in the extracorporeal circuit because, when they reach the systemic circulation of the patient, they are rapidly metabolized to bicarbonate ions. The subject of patent application PCT/EP00/03583 is a solution of a certain composition. [0007] [0007]FIG. 2 shows a device for treating blood by extracorporeal circulation 1 described in patent application PCT/EP00/03583. This device 1 comprises a filter 2 having a first chamber 3 and a second chamber 4 separated by a semi-permeable membrane 5. The device comprises an arterial line 6 connected to the first chamber 3 of the filter for the circulation of blood taken from a patient 7, and a venous line 8 issuing from the first chamber of the filter. A pre-infusion channel 9 containing an anticoagulant, trisodium citrate, is connected to a container 10 comprising a solution of citrate ions and is linked to the arterial line 6, the function of the solution being to prevent coagulation of the blood outside the patient's body. A purge channel 11 is linked to the outlet of the second chamber 4 of the filter, and an air separator 12 is linked on the venous line 8. [0008] The venous line 8 comprises, in addition to the bubble trap 12, a channel 13 connected to a container 14 comprising a solution for re-establishing the ionic equilibrium of the blood. The citrate solution renders the blood anticoagulable by decalcifying it upstream of the filter. This channel 13 is linked downstream of the bubble trap 12, that is to say downstream in the direction of circulation of the blood in the venous line 8 before the blood is returned to the patient 7. [0009] The reason is that, in order to re-establish correct haemostasis, the ionic equilibrium of the blood must be re-established, specifically by recalcifying it, after leaving the filter. [0010] The teaching of this document comprises a safety device with which it is possible to detect any air bubbles present at the start of the venous line. By contrast, the device described does not have any safety means for detecting and trapping any air bubbles in the post-infusion line linked to the venous line, and return of air to the systemic circulation of the patient, which is very dangerous for said patient, is possible. [0011] In seeking to solve this problem, the persons skilled in the art have tried linking the post-infusion line, containing an infusion solution of substitution, directly to the bubble trap of the venous line and not downstream thereof. Moreover, the bubble detector has been placed on this bubble trap. In this way, a single device makes it possible simultaneously to separate and detect the air bubbles coming from, on the one hand, the blood liquid extracted from the filter and, on the other hand, coming from the post-infusion liquid. [0012] However, in trials carried out with this set-up, it has been found, especially in prolonged operation, for example with slow blood flowrates in an intensive care unit, that although the problem of air bubbles in the two liquids is solved, a new problem arises: namely that of coagulation within the bubble trap. This is because the blood liquid extracted from the filter and arriving in the bubble trap comprises an anticoagulant liquid which has been injected in pre-infusion into the patient's blood during its passage through the arterial line. Moreover, the bubble trap also receives an infusion solution of substitution, whose effect is to neutralize the anticoagulant effect of the pre-infusion solution. The structure of the bubble trap is such that on the one hand the liquid passing inside the latter is in contact with the air and the risk of coagulation is present, and, on the other hand, as the bubble trap has a greater diameter than the diameter of the venous line, the flowrate of liquid is thereby diminished and the phenomenon of coagulation thereby promoted. [0013] It is also known in U.S. Pat. No. 5,330,425 (Utterberg) a device concerning the injection in the venous line of drugs and the like. It is also known an haemodialysis machine having an air-detector/line clamp assembly mounted on the venous line typically at least two inches below a venous chamber, in which it is possible to design a venous bloodline wherein an injection site is placed in the tubing downstream of the venous chamber, yet upstream of the air-detector/line clamp. [0014] Another prior art is the patent U.S. Pat. No. 4,490,135 (Troutner) which discloses a single needle haemodialysis system having two air detectors on the venous line. [0015] There is therefore the twin problem of detecting the bubbles in each of the two liquids using-a device of simple structure, and of preventing coagulation of the blood throughout the extracorporeal circuit. [0016] The object of the present invention is to make available a device with which it is possible to solve this problem. [0017] To achieve this object, the invention provides a device for treating blood by extracorporeal circulation (101) comprising: [0018] a filter (102) having a first chamber (103) and a second chamber (104) separated by a semi-permeable membrane (105), [0019] an arterial line (106) connected to the first chamber (103) of the filter (102), [0020] a venous line (108) issuing from the first chamber (103) of the filter (102), [0021] a channel (109) used for pre-infusion of a substance for regional anticoagulation and linked to the arterial line (106), [0022] a purge channel (110) issuing from the second chamber (104) of the filter (102), [0023] an air separator (112) on the venous line (108), [0024] a line (112) for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood downstream of the air separator (111), [0025] an air detector (113) downstream of the post-infusion line (112). [0026] The invention also relates to a disposable venous line (108) for use in a circuit for extracorporeal circulation of blood having undergone pre-infusion of anticoagulant, comprising: [0027] a first channel (134) having a first connector (135) for linking to a filter and a second connector (136), [0028] an air separator (111) linked to the second connector (136) downstream of the first channel (134), [0029] a second channel (137) having a third connector (138) for linking to the outlet of the air separator (111) and a fourth connector (139) for linking to the blood access of a patient, [0030] a fifth connector (140) for linking a line (112) for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood, the fifth connector permitting fluid communication with the second channel (137), [0031] a first part (141) of the second channel (137) connectable to an air detector (113) and placed downstream of the fifth connector (140). [0032] The invention also concerns a device for treating blood by extracorporeal circulation comprising said disposable venous line and according to the alternative embodiments of the disposable venous line. [0033] Finally, the invention relates to a method of treating blood, comprising the following steps: [0034] infusing a substance for regional anti-coagulation into what is called an arterial line carrying blood which has been taken beforehand from a patient, [0035] passing the extracted blood through a filter, [0036] after passage of the blood through the filter, eliminating the possible presence of air in the blood circulating in what is called a venous line, [0037] after possible elimination of the air, infusing a solution at least partially re-establishing the ionic equilibrium of the blood, [0038] after infusion of solution to re-establish the ionic equilibrium, detecting the possible presence of air, [0039] in the event of air being detected, clamping what is called the venous line downstream of the post-infusion, without passing through a second air separator placed downstream of the first air separator. [0040] The invention also concerns a method of extracorporeal blood treatment, comprising the following steps: [0041] extracting blood from a patient at a given flowrate, [0042] infusing a substance for regional anti-coagulation into the extracted blood, [0043] passing the extracted blood through a filter, [0044] after passage of the blood through the filter, eliminating the possible presence of air in the blood passing through a venous line, [0045] after possible elimination of air, infusing a solution at least partially re-establishing the ionic equilibrium of the blood, [0046] after infusion of solution to re-establish the ionic equilibrium, detecting the possible presence of air, [0047] in the event of air being detected, clamping the venous line downstream of the post-infusion, [0048] returning the blood to the patient, without passing through a second air separator placed downstream of the first air separator.
[0049] Other advantages and characteristics of the invention will become evident from reading the description which follows. [0050] Reference will be made to the attached drawings, in which: [0051] [0051]FIG. 1 shows the prior art in terms of an apparatus for extracorporeal treatment of blood with prevention of anticoagulation by heparin; [0052] [0052]FIG. 2 shows the prior art in terms of an apparatus for extracorporeal treatment of blood with prevention of anticoagulation by citrate; [0053] [0053]FIG. 3 shows the device for treating blood by extracorporeal circulation according to the invention; [0054] [0054]FIG. 4 shows a disposable line for treating blood by extracorporeal circulation according to the invention.
[0055] [0055]FIG. 3 shows the device for extracorporeal treatment of blood according to the invention, set up to carry out dialysis treatment. The device for treating blood by extracorporeal circulation 101 according to the invention comprises a filter 102 having a first chamber 103 and a second chamber 104 separated by a semipermeable membrane 105. Depending on the membrane, the filter 105 can be a haemofilter, a plasma filter, a dialyser, or a filter of another type. As regards the membrane, the membranes used are hollow-fibre membranes or sheet or tube membranes. An arterial line 106 is connected to the first chamber 103 of the filter for circulation of blood taken from a patient 107. A venous line 108 is connected to the outlet of the first chamber 103 of the filter. A channel 109 for pre-infusion of a substance for regional anticoagulation is linked to the arterial line 106. A purge channel 110 is connected to the outlet of the second chamber 104 of the filter. An air separator 111 is placed on the venous line 108 and a post-infusion line 112 for a solution at least partially re-establishing the ionic equilibrium is placed downstream of the air separator 111, that is to say downstream in the direction of circulation of the blood in the venous line 108. Finally, an air detector 113 is placed downstream of the post-infusion line 112. [0056] No other air separator is inserted downstream of the air detector 113. The air separator 111 can also be the only air separator present in the venous line 108 and does not contain an air detector. [0057] In this way, the air bubbles possibly caused by the post-infusion remain separable with a line comprising a single air separator, without bringing about undesired coagulation in the extracorporeal circuit, in particular in the air separator. [0058] The venous line 108 comprises a channel which can receive an occlusion means 114 downstream of the air detector. The occlusion means 114 comprises a clamp or a valve of another structure. In the event of air being detected, this means makes it possible to arrest the return of blood to the patient in order to eliminate the air bubbles detected. [0059] The post-infusion line 112 is mounted immediately upstream of the air detector 113. Moreover the tube portion extending between the air detector and the connector to the patient is adapted not to receive any further injection device. The air detector operates as close as possible to the venous line connector 108 which is designed to receive a vascular access device 200 such as for instance a needle or a catheter. Indeed the air detector operates directly upstream the patient venous line conncetor 139. [0060] Thus, the anticoagulant power of the pre-infusion solution is used through the greatest possible extent of the device. [0061] The air separator 111 comprises a bubble trap. The solution for regional anticoagulation contains citrate ions, for example trisodium citrate dihydrate or a solution of Anticoagulant Citrate Dextrose (ACD), comprising trisodium citrate dihydrate and citric acid monohydrate. [0062] The solution at least partially re-establishing the ionic equilibrium of the blood contains calcium ions. This solution can contain an isotonic solution comprising calcium chloride, potassium chloride and magnesium chloride. [0063] Referring again to the sense of blood flow within the arterial line, the pre-infusion line 109 is connected to the arterial line upstream of any means 115 for regulating the flow rate of liquidin the arterial line 108. According to one embodiment the pre-infusion line 109 is connected to the arterial line 106 as close as possible (immediately downstream of the patient arterial line connector 239 in reference to the patient blood flow) of the arterial line connector 239 to the patient which again is designed to receive a vascular access device 201 such as for instance a needle or a catheter. [0064] In this way, the anticoagulation power of the pre-infusion solution is immediately available as soon as patient blood enters into the extracorporeal circuit. [0065] The arterial line 106 is operationally associated with a first means 115 of regulating the flowrate of blood. [0066] The pre-infusion line is operationally associated with a second means 119 of regulating the flowrate of liquid. [0067] The post-infusion line 112 is operationally associated with a third means 121 of regulating the flowrate of liquid. [0068] The purge line 110 issuing from the second chamber 104 of the filter 102 comprises a fourth means 123 of regulating the flowrate of liquid and a first means 124 of measuring the flowrate of liquid. [0069] A calculation and control unit (CPU) 125 is able to receive the signals emitted by a first means 124 of measuring the flowrate operating on the purge channel 110 and for controlling one or more means 115, 119, 121, 123 of regulating the flowrate of liquid in order to initiate a haemofiltration operating mode. [0070] The device for treating blood by extracorporeal circulation 101 comprises an intake line 126 to the second chamber 104 of the filter 102 connecting up with a source 127 of dialysis liquid, for example a container of sterilized liquid or a device for preparing liquid on line. [0071] The citrate ions bind naturally to the calcium ions. This is why the dialysis liquid does not comprise calcium ions. This prevents reaction of the citrate contained in the pre-infusion with calcium which would be contained in the dialysis liquid. The citrate contained in the pre-infusion thus reacts solely with the calcium contained in the blood, and the anticoagulant power of the citrate is not attenuated by the dialysis liquid. [0072] The intake line 126 comprises a fifth means 128 of regulating the flowrate of liquid and a second means 129 of measuring the flowrate of liquid. [0073] A calculation and control unit (CPU) 125 is able to receive the signals emitted by one or more means 124, 129 of measuring the flowrate of liquid and for controlling one or more means 115, 119, 121, 123, 128 of regulating the flowrate of liquid in order to initiate a haemofiltration or haemodiafiltration operating mode. [0074] Each means of regulating the flowrate of liquid 115, 119, 121, 123, 128 comprises a pump or a valve. Each means of measuring the flowrate of liquid 124, 129 comprises a flow meter. [0075] A first balance 130 is provided for weighing a first reservoir 131 connected to the pre-infusion line 109 and containing the pre-infusion liquid; and a second balance 132 is provided for weighing a second reservoir 133 connected to the post-infusion line 112 and containing the post-infusion liquid. [0076] The calculation and control unit 125 is able to receive the signals emitted by at least one of the two balances 130, 132. It controls one or more means 119, 121 of regulating the flowrate of liquid by periodically calculating the actual flowrate or a parameter which is a function of the actual flowrate. [0077] Thus, the quantities of anticoagulant and of solution for re-establishing the ionic equilibrium can be known and controlled during the treatment. Knowing said weights, the calculation and control unit (125) is able to directly control the means of regulating the flowrate of liquid in order to obtain a desired quantity of pre-infusion solution and/or post-infusion solution in the extracorporeal circuit. [0078] [0078]FIG. 4 shows the disposable venous line 108 for use in a circuit for extracorporeal circulation of blood having undergone pre-infusion of anticoagulant, said line comprising a first channel 134 having a first connector 135 for linking to a filter and a second connector 136. An air separator 111 is linked to the second connector 136 downstream of the first channel 134, that is to say downstream in the direction of the blood. The disposable venous line 108 also comprises a second channel 137 having a third connector 138 for linking the outlet of the air separator 111 and a fourth connector 139 for linking to the blood access of a patient. A fifth connector 140 is placed to connect a line 112 for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood, the fifth connector 140 permitting fluid communication with the second channel 137. The line additionally comprises a first part 141 of the second channel 137 capable of cooperating with the air detector 113 and placed downstream of the fifth connector 140. [0079] The first part 141 is marked visually, for example by different colours, a relief, by a tube differentiated in terms of material, shape or size from the rest of the line. [0080] The post-infusion line 112 is linked to the second connector 140 in order to infuse the solution at least partially re-establishing the ionic equilibrium of the blood. [0081] The fifth connector 140 will be connected on the second channel 137 as close as possible to the fourth connector 139. [0082] The tube portion extending between the fifth connector 140 and the fourth connector 139 is continuous and adapted not to receive any further line or any further injection device. [0083] The fifth connector 140 placed on the second channel 137 can be a removable connector. Alternatively, the connector 140 can comprise an end portion of the tube 112 fixed to the line 137. [0084] No other air separator is inserted downstream of the first part 141 of the second channel 137 connectable to the air detector 113. [0085] The air separator 111 can be the only air separator present in the disposable venous line 108. [0086] The air separator 111 comprises a bubble trap. [0087] The solution at least partially re-establishing the ionic equilibrium of the blood contains citrate ions. [0088] The post-infusion line 112 comprises a second part 143 connectable to a means of regulating the flowrate of the perfusion line, said second part 143 being maintained in a U-shape by means of a small bar fixing two points of the line, in order to facilitate coupling with the pump. [0089] The second part 143 is marked visually, for example by different colours, by a relief, by a tube differentiated in terms of material, shape or size from the rest of the line. [0090] The first connector 135 of the first channel 134 is either removable or fixed. [0091] The second connector 136 of the first channel 134 and the third connector 138 of the second channel 137 are fixed. [0092] The fourth connector 139 of the second channel 137 is either fixed or removable. [0093] The present invention affords numerous advantages. The air bubbles possibly introduced by the post-infusion remain detectable with a line comprising a single and unique bubble trap. The device thus has a simple and inexpensive structure. [0094] Moreover, the use of said device, of said line and of said method does not entail undesired coagulation in the extracoporeal circuit, in particular in the bubble trap where the contact of air with the blood is possible and where the speed of displacement is less than in the rest of the venous line on account of the diameter of the bubble trap being larger than that of the rest of the line. This therefore results in effective prevention of administration of air to the patient. [0095] Thus, the anticoagulant power of the pre-infusion solution is used throughout the greatest possible extent of the device because the pre-infusion of anticoagulant is injected as far as possible upstream in the extracorporeal circuit and the post-infusion of solution re-establishing ionic equilibrium is linked as close as possible to the blood access to the patient, that is to say as far downstream as is possible on the venous line. This link prevents coagulation throughout the portion of line where the need for anticoagulation arises, particularly where contact between the blood and air is possible. The configuration of the venous line is all the more advantageous since, as a result of the location of the site of administration of the neutralizing solution, the blood, no longer comprising anticoagulant substance, at no point can come into contact with the air. [0096] In addition, the invention is very advantageous in cases where a device is operating for long periods, for example at a low blood flowrate in an intensive care unit, that is to say in acute treatment with a low flowrate and long duration. [0097] It has been confirmed that the dialysis values measured during extracorporeal treatment according to the invention remain as stable as with an anticoagulant of the heparin type re-injected into the patient. [0098] Thus, the result of anticoagulation is very advantageous because the coagulation time is increased fourfold between the perfusion of anticoagulant and the perfusion of neutralizing solution compared to the blood circulating in the rest of the circuit. [0099] Finally, at the end of the session, the compression time needed for haemostasis of the fistula is reduced compared to treatment with administration of heparin because the blood re-injected into the patient has recovered its normal coagulating power. Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS3946731 *Jul 31, 1974Mar 30, 1976Lichtenstein Eric StefanApparatus for extracorporeal treatment of bloodUS4464164 *Sep 24, 1982Aug 7, 1984Extracorporeal Medical Specialties, Inc.Flowrate control for a blood flow systemUS4490135 *Sep 24, 1982Dec 25, 1984Extracorporeal Medical Specialties, Inc.Single needle alternating blood flow systemUS4500309 *May 7, 1982Feb 19, 1985The Kansas University Endowment AssociationMethod for regional anticoagulation during extracorporeal dialysisUS4571244 *May 7, 1984Feb 18, 1986Biogenesis, Inc.System for removing gas bubbles from liquidsUS4894150 *Jun 2, 1988Jan 16, 1990Schurek Hans JoachimMechanical device for simplifying fluid balance in hemofiltrationUS5032615 *Oct 31, 1989Jul 16, 1991The Regents Of The University Of CaliforniaContinuous hemodialysis using citrateUS5205153 *Jan 23, 1992Apr 27, 1993Cobe Laboratories, Inc.Method and apparatus for detection of air bubbles in tubingUS5330425 *May 11, 1993Jul 19, 1994Utterberg David SBlow molded venous drip chamber for hemodialysisUS5344568 *May 17, 1993Sep 6, 1994Children's Hospital Medical CenterHemofiltration system and methodUS5470483 *Mar 21, 1994Nov 28, 1995Hospal IndustrieDevice and method for controlling the balance of fluids in an extracorporeal blood circuitUS5529685 *Jul 2, 1993Jun 25, 1996Senko Medical Instrument Mfg. Co., Ltd.Dialysis system for returning blood in the system after the completion of dialysisUS5578223 *Feb 3, 1995Nov 26, 1996Hospal IndustrieArtificial kidney and method for adjusting a concentration of substance in blood using thereofUS5650071 *Jun 7, 1995Jul 22, 1997Cobe Laboratories, Inc.Technique for priming and recirculating fluid through a dialysis machine to prepare the machine for useUS5676841 *Jun 7, 1995Oct 14, 1997Baxter International Inc.Blood processing systems and methods which monitor citrate return to the donorUS5762805 *Jun 7, 1995Jun 9, 1998Cobe Laboratories, Inc.Technique for extracorporeal treatment of bloodUS6123847 *Aug 20, 1998Sep 26, 2000Hospal IndustrieDevice and process for regulating the sodium concentration in a dialysis liquid with a view to a prescriptionUS6454736 *May 28, 1999Sep 24, 2002Fresenius AgMethod of filling a tube system with a rinsing liquid and a tube system for use with this methodUS6561997 *Apr 21, 2000May 13, 2003The Regents Of The University Of MichiganExtracorporeal fluid circuit and related methodsUS6572576 *Jul 7, 2001Jun 3, 2003Nxstage Medical, Inc.Method and apparatus for leak detection in a fluid lineUS6726647 *Oct 22, 1999Apr 27, 2004Gambro AbMethod and device for measuring access flowUS6743191 *Apr 20, 2000Jun 1, 2004Edwards Lifesciences AgSubstitution infusion fluid and citrate anticoagulationUS7029456 *Oct 15, 2003Apr 18, 2006Baxter International Inc.Medical fluid therapy flow balancing and synchronization systemUS20020004530 *May 23, 2001Jan 10, 2002Warnock David G.Use of citrate-containing dialysate for renal dialysis treatmentUS20030045827 *Dec 26, 2001Mar 6, 2003Volker NierMethod for determining concentration; a dialyser* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS7309323 *Sep 14, 2004Dec 18, 2007National Quality Care, Inc.Wearable continuous renal replacement therapy deviceUS7686778Jan 14, 2004Mar 30, 2010Nxstage Medical, Inc.Waste balancing for extracorporeal blood treatment systemsUS7892196Nov 1, 2007Feb 22, 2011Fresenius Medical Care Holdings, Inc.Wearable continuous renal replacement therapy deviceUS8133194Jul 27, 2007Mar 13, 2012Henry Ford Health SystemSystem and method for delivery of regional citrate anticoagulation to extracorporeal blood circuitsUS8137299Oct 6, 2009Mar 20, 2012Fresenius Medical Care Holdings, Inc.Wearable ultrafiltration deviceUS8206331Jun 26, 2012Fresenius Medical Care Holdings, Inc.Wearable ultrafiltration deviceUS8211048 *Feb 22, 2007Jul 3, 2012Henry Ford Health SystemSystem and method for delivery of regional citrate anticoagulation to extracorporeal blood circuitsUS8235931Aug 5, 2009Aug 7, 2012Nxstage Medical, Inc.Waste balancing for extracorporeal blood treatment systemsUS8372025Feb 12, 2013Baxter International Inc.Automation and optimization of CRRT treatment using regional citrate anticoagulationUS8945036Feb 14, 2012Feb 3, 2015Henry Ford Health SystemSystem and method for delivery of regional citrate anticoagulation to extracorporeal blood circuitsUS9022966Jun 30, 2011May 5, 2015Nikkiso Co., Ltd.Regional citrate anticoagulationUS20050101901 *Sep 14, 2004May 12, 2005Victor GuraWearable continuous renal replacement therapy deviceUS20050143684 *Feb 22, 2005Jun 30, 2005Charles BolanApheresis methods and devicesUS20070038191 *Jan 14, 2004Feb 15, 2007Burbank Jeffrey HWaste balancing for extracorporeal blood treatment systemsUS20070066928 *Sep 21, 2006Mar 22, 2007Jean-Michel LannoyAutomation and optimization of CRRT treatment using regional citrate anticoagulationUS20080015487 *Jul 27, 2007Jan 17, 2008Henry Ford Health SystemSystem and Method for Delivery of Regional Citrate Anticoagulation to Extracorporeal Blood CircuitsUS20080058696 *Nov 1, 2007Mar 6, 2008National Quality Care, IncWearable continuous renal replacement therapy deviceUS20090221948 *Feb 22, 2007Sep 3, 2009Henry Ford Health SystemSystem and method for delivery of regional citrate anticoagulation to extracorporeal blood circuitsUS20100022936 *Jan 28, 2010National Quality Care, Inc.Wearable ultrafiltration deviceUS20100094193 *Dec 11, 2009Apr 15, 2010National Quality Care, Inc.Wearable ultrafiltration deviceUS20110142700 *Nov 15, 2010Jun 16, 2011Fresenius Medical Care Holdings, Inc.Dual-ventricle pump cartridge, pump, and method of use in a wearable continuous renal replacement therapy deviceEP1998826A2 *Feb 22, 2007Dec 10, 2008Henry Ford Health SystemSystem and method for delivery of regional citrate anticoagulation to extracorporeal blood circuitsEP1998826A4 *Feb 22, 2007Feb 8, 2012Ford Henry Health SystemSystem and method for delivery of regional citrate anticoagulation to extracorporeal blood circuitsEP2526981A1 *May 25, 2012Nov 28, 2012Bellco S.r.l.Infusion assembly of a dialysis machineEP2653178A1Apr 16, 2012Oct 23, 2013Zentrum f�r biomedizinische Technologie der Donau- Universit�t KremsSafety device for extracorporeal blood treatmentEP3042673A1 *Oct 31, 2007Jul 13, 2016Gambro Lundia ABInfusion site for improved mixing of fluidsWO2007038347A1 *Sep 22, 2006Apr 5, 2007Edwards Lifesciences CorporationAutomation and optimization of crrt treatment using regional citrate anticoagulationWO2007101064A2 *Feb 22, 2007Sep 7, 2007Henry Ford Health SystemSystem and method for delivery of regional citrate anticoagulation to extracorporeal blood circuitsWO2007101064A3 *Feb 22, 2007Nov 6, 2008Ford Henry Health SystemSystem and method for delivery of regional citrate anticoagulation to extracorporeal blood circuitsWO2013156435A1Apr 15, 2013Oct 24, 2013Zentrum F�r Biomedizinische Technologie Der Donau-Universit�t KremsSafety apparatus for extracorporeal blood treatment* Cited by examinerClassifications U.S. Classification604/5.01, 604/6.07, 210/739, 604/6.09International ClassificationA61M1/34, A61M1/36Cooperative ClassificationA61M1/342, A61M1/3431, A61M1/3672, A61M1/3675, A61M1/3458, A61M1/3626European ClassificationA61M1/36H, A61M1/34ELegal EventsDateCodeEventDescriptionDec 19, 2003ASAssignmentOwner name: GAMBRO LUNDIA AB, SWEDENFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOSPAL INTERNATIONAL MARKETING MANAGEMENT SNC;REEL/FRAME:014832/0624Effective date: 20021219Owner name: HOSPAL INTERNATIONAL MARKETING MANAGEMENT SNC, FRAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BENE, BERNARD;REEL/FRAME:014832/0626Effective date: 20021219Aug 5, 2008CCCertificate of correctionMay 21, 2009ASAssignmentOwner name: CITICORP TRUSTEE COMPANY LIMITED, UNITED KINGDOMFree format text: IP SECURITY AGREEMENT SUPPLEMENT;ASSIGNOR:GAMBRO LUNDIA AB;REEL/FRAME:022714/0702Effective date: 20090331Owner name: CITICORP TRUSTEE COMPANY LIMITED,UNITED KINGDOMFree format text: IP SECURITY AGREEMENT SUPPLEMENT;ASSIGNOR:GAMBRO LUNDIA AB;REEL/FRAME:022714/0702Effective date: 20090331Sep 23, 2011FPAYFee paymentYear of fee payment: 4Dec 29, 2011ASAssignmentOwner name: GAMBRO LUNDIA AB, COLORADOFree format text: RELEASE OF SECURITY INTEREST IN PATENTS;ASSIGNOR:CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT;REEL/FRAME:027456/0050Effective date: 20111207Sep 24, 2015FPAYFee paymentYear of fee payment: 8RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services